Wendy B. Stevens, MD

Radboud UMC, Nijmegen, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON /LLPC, Netherlands

N/A

Poster(s):

• 3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)